Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke
ConditionAcute Ischemic Stroke
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorYing Gao
About this trial
The primary purpose of this study is to investigate the effectiveness of Ginkgo Diterpene Lactone Meglumine (GDLM) for patients with acute ischemic stroke (AIS) in real-world settings.
Eligibility criteria
Qualifiers
aged ≥18 years, regardless of gender
within 48 hours of stroke onset of ischemic stroke
patient or their legally authorized representative (LAR) has signed informed consent or legally authorized oral consent with documentation
Disqualifiers
mRS score of 2 or more prior to onset
total hospital stay less than 7 days
use of other ginkgo-derived preparations except GDLM
current or planned participation in any other interventional clinical trials
Trial design
Treatments tested in this trial
- Ginkgo Diterpene Lactone Meglumine
Treatment groups
4,460 Participants
are divided into 2 treatment groupsSponsors and collaborators
Ying Gao
Lead sponsor
Dongzhimen Hospital, Beijing
Sponsor institution
Source ClinicalTrials.gov